Effects of CD40 pathway on the biological behavior of pancreatic cancer cells

doi:10.12092/j.issn.1009-2501.2018.07.006

Abstract

Abstract:

AIM: To study the effect of CD40L on the biological characteristics and stenness of pancreatic cancer cells. METHODS: The effect of different concentrations of sCD40L (0, 1, 2, 4 μg/mL) on the proliferation of human pancreatic cancer cell line panc02 was analyzed by CCK-8 live cell counting assay. Apoptosis was detected by Annexin V/PI double staining; migrational ability was detected by Cell Scratch Assays. Q-PCR was used to detect the levels of c-Myc, OCT-4 and Sox-2 after panc02 treatment for 4 h/mL sCD40L. A Balb/c nude mouse model of pancreatic cancer was established and randomly divided into two groups: control group (normal saline) and sCD40L (10 mg/kg) group. They were injected intraperitoneally with sCD40L 10 mg/kg and an equal volume of saline for three times a day. Tumor volume was measured using vernier calipers at 0, 7th, 14th, 21st, and 28th day. RESULTS: Compared with the control group, the growth and migration of panc02 decreased significantly after sCD40L treatment (1, 2, 4 μg/mL for 96 h), and apoptosis was promoted in a dose-dependent manner (P＜0.01). sCD40L (4 μg/mL) significantly inhibited the expression of c-Myc, OCT-4, Sox-2 of panc02 (P＜0.01). In the nude mice tumor-bearing experiment, compared with the control group, sCD40L significantly inhibited the tumor volume at 28th day (P＜0.01, 252±13 vs. 189±9). CONCLUSION: Activation of CD40 pathway inhibits proliferation, migration and apoptosis of pancreatic cancer cells as well as the proliferation of pancreatic cancer cell lines in vivo. This effect may be related to the change of stemness in pancreatic cancer cell lines.

Key words: pancreatic cancer, proliferation in vivo and in vitro, CD40/CD40L, stemness

CLC Number:

R965.2

ZHANG Guifeng, CAI Jiaqin, CUI Tongjian, LIU Zhenhua, XU Zhixian. Effects of CD40 pathway on the biological behavior of pancreatic cancer cells[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 755-760.

References

［1］Chang BW, Siccion E, Saif MW. Updates in locally advanced pancreatic cancer. Highlights from the "2010 ASCO Annual Meeting"［J］. JOP, 2010, 11(4): 313-316.

［2］Goldstein D, El-Maraghi RH, Hammel P, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial［J］. J Natl Cancer Inst, 2015, 107(2): 413.

［3］张正茂，张超单，保恩. CD40和CD40L与肿瘤关系的研究进展［J］. 中国免疫学杂志，2007，7（23）: 667-670.

［4］Robinson JW, Li JY, Walker LD, et al. T cell-expressed CD40L potentiates the bone anabolic activity of intermittent PTH treatment ［J］. J Bone Miner Res, 2015, 30(4): 695-705.

［5］Chonan M, Saito R, Shoji T, et al. CD40/CD40L expression correlates with the survival of patients with glioblastomas and anaugmentation in CD40 signaling enhances the efficacy of vaccinations against gliomamodels［J］. Neuro Oncol, 2015, 17(11): 1453-1462.

［6］Eckert RL, Fisher ML, Grun D, et al. Transglutaminase is a tumor cell and cancer stem cell survival factor［J］. Mol Carcinog, 2015,54(10): 947-958.

［7］De La Cruz MS , Young AP , Ruffin MT . Diagnosis and management of pancreatic cancer［J］. Am Fam Physician, 2014 ,89(8): 626-632.

［8］Brunekreeft KL, Strohm C, Gooden MJ, et al. Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death［J］. Mol Cancer, 2014, 13: 85.

［9］Hojer C, Frankenberger S, StroblL J,et al. B-cell expansion and lymphoma genesis induced by chronic CD40 signaling is strictly dependent on CD19［J］. Cancer Res, 2014,74(16): 4318-4328.

［10］Li R, Chen WC, Pang XQ, et al. Influence of sCD40L on gastric cancer celllines［J］. Mol Biol Rep, 2011, 38(8): 5459-5464.

［11］Fanale M,Assouline S,Kuruvilla J,et al.Phase IA/II,multicentre,open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma［J］.Br J Haematol,2014 ,164(2):258-265.

［12］Pang X, Zhang L, Wu J, et al. Expression of CD40/CD40L in colon cancer, and its effect on proliferation and apoptosis of SW48 colon cancer cells［J］. J Buon, 2017, 22(4): 894-899.

［13］Marigo I, Zilio SZ, Desantis GT, et al. Cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells［J］. Cancer Cell, 2016, 30(3): 377-390.

［14］Cao C, Sun L, Mo W, et al. Quercetin Mediates β-catenin in pancreatic cancer stem-like cells［J］. Pancreas, 2015, 44(8): 1334-1339.

［15］Gu C, Banasavadi-Siddegowda YK, Joshi K, et al. Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner［J］. Stem Cells, 2013, 31(5): 870-881.

[1]	ZHANG Jinghui, WEI Haoliang, WANG Li, LI Jingkai, ZHANG Baolai, YANG Xiaolai. Effects of AMI-1 on the activity of pancreatic cancer cells in vitro by down-regulating PRMT5 expression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 601-608.
[2]	ZHENG Ying, ZHANG Ling, YAO Li, WANG Qianhe, ZHU Kexiang. Research progress of PARP inhibitors in pancreatic cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 108-115.
[3]	ZHANG Chenhan, NIE Jingyun, XIN Pengfei, CHAI Chen, LI Bo. Research progress of melatonin and pancreatic diseases#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(11): 1309-1314.
[4]	SONG Haiyan, ZHANG Yimin, ZHOU Zhixin, CHENG Huixin, FU Shengqi. Effect of obatoclax in combination with 5-fluorouracil on the apoptosis of pancreatic cancer cells under hypoxic [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 887-891.
[5]	WANG Wanming, DONG Jiazhong, GUAN Shuming. Effect of USP22 on gemcitabine chemoresistance in human pancreatic cancer cell [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 412-417.
[6]	HOU Xinfang, SONG Haiyan, ZHOU Zhixin, DENG XiaoHui, ZHANG Yimin, CHENG Huixin. Effects of obatoclax plus 5-Fluorouracil on the epithelial mesenchymal transition of pancreatic cancer cells under hypoxia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(10): 1117-1122.
[7]	QU Pi-sheng, FU Shuang, HUANG Li-xia, WANG Zhen, TAO Fan, ZHENG Han-guang. Influence of morphine consumption on pancreatic cancer under neurolytic celiac plexus block [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(5): 557-560.
[8]	HUANG He, WU Pei, HONG Shu-jian, MAO Jia-ding, RUI Jing. Construction of eukaryotic expression vector expressing double shRNA sections targeting Survivin gene in Bx-PC3 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(6): 655-658.